In the age of artificial intelligence, speed is often mistaken for rigor. Nowhere is this more dangerous than in oncology, where treatment decisions can mean the difference between life and death.
Some technology companies tout “systematic literature reviews” (SLRs) generated in minutes by chatbots that claim to scan thousands of papers across the internet. The appeal is obvious: quick, accessible, and seemingly comprehensive. But in reality, these outputs are neither systematic nor reliable. For oncologists, payers, and researchers, understanding the distinction between a true SLR and a chatbot’s surface-level search is not just academic—it’s essential.
The Gold Standard: What a True SLR Involves
Systematic literature review is the gold standard for evidence synthesis in medicine. It is the foundation of evidence-based practice because it minimizes bias, ensures completeness, and enables decisions to rest on the strongest available science.
A rigorous SLR begins with a protocol: a predefined roadmap that frames the research question and methods. It requires carefully constructed search strategies, typically using combinations of keywords and controlled vocabulary, to capture every relevant publication across peer-reviewed databases.
The process doesn’t stop there. Grey literature—such as abstracts from scientific conferences—must also be included, since cutting-edge oncology data often appears in congress presentations long before it reaches a journal.
From there, studies undergo multi-step screening against strict inclusion and exclusion criteria: patient population, interventions, comparators, outcomes, and study design (the classic PICO framework). Each selected paper is then critically appraised for quality and relevance. Only after this painstaking filtering does the work of synthesis and interpretation begin.
This is not a clerical exercise. It requires advanced training, sound judgment, and clinical insight to evaluate conflicting results, contextualize findings, and translate them into actionable conclusions.
Why Chatbots Fall Short
Chatbots, even those powered by large language models (LLMs), cannot replicate this process. At best, they skim unstructured text. At worst, they hallucinate citations or omit critical studies. They lack protocols, inclusion criteria, appraisal of study quality, or a transparent audit trail. What results may look convincing on the surface—but lacks the depth and reliability required in oncology.
When a chatbot says it can “review 1,000 studies in seconds,” what it’s really doing is producing a text summary based on whatever sources it happens to ingest. There is no guarantee that the sources are peer-reviewed, complete, current, or even real. That is not an SLR.
Why It Matters in Oncology
Oncology is not forgiving of shortcuts. Selecting the right therapy for a patient is an exercise in precision: choosing between regimens, sequencing targeted therapies, balancing efficacy and toxicity, and staying current on breakthroughs that can extend survival or improve quality of life.
In this context, incomplete, outdated, or fabricated evidence isn’t a minor flaw—it’s a threat to patient safety. The rigor of a systematic literature review is not a “nice to have”; it’s the foundation for making responsible decisions in cancer care.
The Path Forward
AI absolutely has a role to play in evidence synthesis. When paired with human expertise and transparent methodology, it can accelerate searches, streamline screening, and reduce administrative burden. But AI must serve the process—not replace it.
In oncology, the choice isn’t between a chatbot and a systematic literature review. It’s between cutting corners and saving lives. The stakes are too high for anything less than living, rigorous, and human-guided evidence.
Anna Forsythe
Anna Forsythe is the Founder and President of Oncoscope-AI, the first platform to bring together real-time oncology treatment data, clinical guidelines, research publications, and regulatory approvals — all in one place, just like Expedia for cancer care. Available free to oncology professionals worldwide, Oncoscope-AI is redefining how cancer care information is accessed and applied.
